| Contributors: |
CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Institut du Cerveau = Paris Brain Institute (ICM); Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS); Centre d'investigation clinique Neurosciences CHU Pitié Salpêtrière (CIC Neurosciences); Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ); Université Paris-Saclay; Centre Hospitalier de Versailles André Mignot (CHV); Centre d'investigation clinique de Toulouse (CIC 1436); Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique CHU Toulouse; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Université de Toulouse (EPE UT); Communauté d'universités et établissements de Toulouse (Comue de Toulouse)-Communauté d'universités et établissements de Toulouse (Comue de Toulouse); Centre d’Excellence en Maladies Neurodégénératives (NeuroToul); Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne); Université Clermont Auvergne (UCA); Institut Pascal (IP); Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA)-Institut national polytechnique Clermont Auvergne (INP Clermont Auvergne); Université Clermont Auvergne (UCA)-Université Clermont Auvergne (UCA); Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes); The Enteric Nervous System in gut and brain disorders U1235 (TENS); Institut National de la Santé et de la Recherche Médicale (INSERM)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE); Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé; Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ); Sponsor of the DIGPD clinical trial was ‘Assistance Publique–Hôpitaux de Paris’. DIGPD was funded by grants from the French Ministry of Health (Programme Hospitalier de Recherche Clinique, AOR0810) and from the French Drug Agency (ANSM-2013). b; DIGPD study group: Jean-Christophe Corvol, Alexis Elbaz, Marie Vidailhet, Alexis Brice, Alexis Elbaz, Fanny Artaud, Frédéric Bourdain, Jean-Philippe Brandel, Jean-Christophe Corvol, Pascal Derkinderen, Franck Durif, Richard Levy, Fernando Pico, Olivier Rascol, Anne-Marie Bonnet, Cecilia Bonnet, Christine Brefel-Courbon, Florence Cormier-Dequaire, Bertrand Degos, Bérangère Debilly, Alexis Elbaz, Monique Galitsky, David Grabli, Andreas Hartmann, Stephan Klebe, Julia Kraemmer, Lucette Lacomblez, Sara Leder, Graziella Mangone, Louise-Laure Mariani, Ana-Raquel Marques, Valérie Mesnage, Julia Muellner, Fabienne Ory-Magne, Violaine Planté-Bordeneuve, Emmanuel Roze, Melissa Tir, Marie Vidailhet, Hana You, Eve Benchetrit, Julie Socha, Fanny Pineau, Tiphaine Vidal, Elsa Pomies, Virginie Bayet, Alexis Brice, Suzanne Lesage, Khadija Tahiri, Hélène Bertrand, Graziella Mangone, Alain Mallet, Coralie Villeret, Merry Mazmanian, Hakima Manseur, Mostafa Hajji, Benjamin Le Toullec, Vanessa Brochard, Monica Roy, Isabelle Rieu, Stéphane Bernard, Antoine Faurie-Grepon |
| Description: |
International audience ; Background Predicting falls in patients with Parkinson's disease (PD) is challenging despite their significant frequency and consequences. Objectives To determine incidences of first fall, walking aid requirement, and identify risk factors of subsequent risk, including factors unrelated to PD. Methods Study in 415 PD patients (DIGPD prospective cohort). Cumulative incidence curves were calculated and Generalized Linear Mixed Models investigated influencing factors. Results Five years after diagnosis, 26.1% of patients experienced falls while only 2.1% required walking aids; after 10 years, it rose to 66.5% and 17%, respectively. Median time to first fall was 7.9 years. Risk factors of falls were cognitive decline, freezing, comorbidities such as diabetes and depression, history of falls particularly in male, or low Body Mass Index (BMIs). Walking aids risk factors were older age, freezing, lower walking speed, higher BMIs, history of walking aid. Conclusions Treatable comorbidities (depression, diabetes, weight regulation) should be addressed in daily care to avoid falls in PD patients. |